An adeno‐associated viral vector‐based approach (ETX101) with cell‐selective expression of a transcription factor upregulating SCN1A expression has entered clinical testing in patients with Dravet syndrome in 2024. This evidence concerns the gene SCN1A and Dravet syndrome.